OMecaMtiv Mecarbil
| Price | $1 |
| Package | 1ASSAYS |
| Min. Order: | 1ASSAYS |
| Update Time: | 2019-09-06 |
Product Details
| Product Name: OMecaMtiv Mecarbil | CAS No.: 873697-71-3 |
| Min. Order: 1ASSAYS | Purity: 95%~99% |
| Supply Ability: per week:100kg | Release date: 2019/09/06 |
Mary014
▼
▲
▼
▲
▼
▲
▼
▲
OMecaMtiv Mecarbil Basic information
Description In vitro In vivo
▼
▲
Product Name:
OMecaMtiv Mecarbil
Synonyms:
CK 1827452 - Omecamtiv Mecarbil | CK-452;OMecaMtiv Mecarbil;OMecaMtiv Mecarbil (CK-1827452);CK1827452;CK-1827452;CK-1827452 (OMecaMtiv Mecarbil);CK 1827452O;mecamtiv mecarbil
CAS:
873697-71-3
MF:
C20H24FN5O3
MW:
401.4346632
EINECS:
Product Categories:
-;Inhibitors
Mol File:
873697-71-3.mol
▼
▲
OMecaMtiv Mecarbil Chemical Properties
▼
▲
Melting point
180℃
▼
▲
Safety Information
▼
▲
▼
▲
MSDS Information
▼
▲
OMecaMtiv Mecarbil Usage And Synthesis
▼
▲
Description
Omecamtiv mecarbil (CK-1827452) is a specific cardiac myosin activator and a clinical drug for left ventricular systolic heart failure. Phase 2.
In vitro
In vitro, Omecamtiv mecarbil selectively activates cardiac myosin by increasing the myosin ATPase rate. In isolated cardiac myocytes, Omecamtiv mecarbil results in increase of myocyte contractility and overcomes of the myosin inhibitor BDM without increasing the calcium transient or inhibiting the PDE pathway. [
In vivo
Omecamtiv mecarbil significantly increases fractional shortening starting at 0.4 mM plasma concentrations in SD rats, sham animals and in rats with heart failure. In conscious dogs with myocardial infarction (MI-sHF), Omecamtiv mecarbil leads to a significant increase in wall thickening (25%), stroke volume (44%), cardiac output (22%) and left ventricular (LV) systolic ejection time (26%). In addition, Omecamtiv mecarbil also results in the decreases of some hemodynamic parameters including heart rate, mean left atrial pressure, and LV end-diastolic pressure. In conscious dogs with left ventricular hypertrophy (LVH-sHF), Omecamtiv mecarbil leads to similar and not statistically different effects on hemodynamic parameters.
Uses
CK 1827452 is a promising new drug in systolic heart failure. It accelerates the transition of myosin into the force-generating state without affecting cardiac myocyte calcium homeostasis. CK 1827452 increases cardiac function by increasing the duration of ejection without changing the rates of contraction.
▼
▲
OMecaMtiv Mecarbil Preparation Products And Raw materials
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates：
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00 |
Shenzhen Excellent Biotech Co., Ltd.
|
2020-08-20 |
China- Since: 2014-12-17
- Address: Zhengzhou High tech Zone, Henan Province, China
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com